Αποτελέσματα Αναζήτησης
4 Ιαν 2023 · Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus’ protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle.
9 Νοε 2023 · Post-exposure prophylaxis (PEP) to prevent HIV acquisition has been recommended for over three decades, but remains underutilised. Over the past decade, clinical trials have established the safety and tolerability of newer PEP regimens, particularly those containing integrase strand transfer inhibitors (INSTIs) combined with a tenofovir and ...
6 Μαρ 2024 · A once-daily oral combination therapy for HIV — bictegravir plus lenacapavir — is more effective than complex regimens are, according to results from a phase 2 study of people with HIV who are virologically suppressed, presented the Conference on Retrovirus and Opportunistic Infections (CROI) in Denver.
18 Νοε 2021 · Cabotegravir (also called Vocabria and made by ViiV Healthcare) and rilpivirine (also called Rekambys and made by Janssen) are given as two separate injections every two months, after an...
23 Δεκ 2021 · In clinical trials, cabotegravir proved to be 69% more effective than oral PrEP in preventing HIV among men who have sex with men.
Subcutaneous implants are a promising technology to enable long-acting parenteral delivery of antiretroviral drugs (ARV) because they may be able to provide protective drugs concentrations for a year or longer following a single implant. The present review covers the current status of preclinical and clinical development of antiretroviral implants.
11 Δεκ 2023 · Cabotegravir is an intramuscular injection administered every 2 months for HIV PrEP; rapid detection of new HIV infection in people taking cabotegravir is an emerging concern. Lenacapavir given subcutaneously every 6 months is promising and currently in clinical trials for HIV PrEP.
